Skip to main content

Contineum Therapeutics, Inc 8-K, filed Nov 3, 2026

Contineum Therapeutics, Inc. (CTNM)

8-K 2026-11-03 For: 2026-11-03
View Original
Added on November 03, 2026

About this 8-K

Contineum Therapeutics, Inc filed this 8-K on November 3, 2026.

Contineum Therapeutics said the PROPEL-IPF trial of PIPE-791 had over 100 sites online in 16 countries, while $244.5 million in cash, cash equivalents and marketable securities was projected to fund operations through mid-2029. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits